Wakefield Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Wakefield Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19M	Buy	14,339 +261	+2%	+$20.9K	0.27%	119
2026 Q1	$1.08M	Buy	14,078 +140	+1%	+$10.9K	0.29%	114
2025 Q4	$1.1M	Buy	13,938 +39	+0.3%	+$3.38K	0.3%	104
2025 Q3	$1.27M	Sell	13,899 -3,209	-19%	-$262K	0.35%	94
2025 Q2	$1.12M	Sell	17,108 -140	-0.8%	-$9.12K	0.31%	106
2025 Q1	$1.15M	Buy	+17,248	New	+$1.03M	0.35%	87
2024 Q4	–	Sell	-13,819	Closed	-$824K	–	148
2024 Q3	$824K	Sell	13,819 -167	-1%	-$10.2K	0.27%	109
2024 Q2	$891K	Sell	13,986 -177	-1%	-$11.5K	0.31%	100
2024 Q1	$979K	Buy	+14,163	New	+$855K	0.34%	84
2023 Q4	–	Sell	-12,350	Closed	-$717K	–	151
2023 Q3	$717K	Sell	12,350 -5,125	-29%	-$296K	0.32%	87
2023 Q2	$941K	Buy	+17,475	New	+$775K	0.37%	73

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wakefield Asset Management's ANIP Position: Q2 2026 in Review

Wakefield Asset Management increased its ANI Pharmaceuticals (ANIP) stake by 1.9% in Q2 2026, buying an estimated $20.9K and bringing the position to 14,339 shares worth $1.19M. The position accounts for 0.27% of the portfolio, ranked #119.

Wakefield Asset Management first reported a position in ANIP in Q2 2023 and has held it in 11 quarters since. The position peaked at $1.27M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Wakefield Asset Management held 14,339 shares of ANI Pharmaceuticals worth $1.19M as of Q2 2026.
Wakefield Asset Management bought 261 ANI Pharmaceuticals shares in Q2 2026, an estimated $20.9K.
ANI Pharmaceuticals made up 0.27% of Wakefield Asset Management's portfolio in Q2 2026, its #119 holding.
Wakefield Asset Management first reported a position in ANI Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
Wakefield Asset Management's ANI Pharmaceuticals position peaked at $1.27M in Q3 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Wakefield Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.